Literature DB >> 30295114

Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).

Olivia Le Saux1, Evelyne Decullier2, Gilles Freyer1, Olivier Glehen3, Naoual Bakrin3.   

Abstract

OBJECTIVE: Despite a high response rate to first-line therapy, prognosis of epithelial ovarian carcinoma (EOC) remains poor. The objective of the present study was to evaluate the frequency of long-term survivors and to identify the prognostic factors associated with long-term survival in a French cohort of 566 patients.
METHODS: Patients treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for EOC in 13 French centers between 1991 and 2010 were included. Long-term survivors were defined as patients who survived more than 5 years after HIPEC and CRS, irrespective of relapse.
RESULTS: Seventy-eight long-term survivors were analyzed. The median follow-up was 74 months. Median age at the time of first HIPEC was 55.4 years (range [22.6-77.6]. Seven patients had advanced EOC and 71 patients had recurrent EOC (37 patients had platinum-resistant EOC and 32 had platinum-sensitive disease). More than half of the long-term survivors had high-grade serous ovarian cancer (HGSOC). In univariate analysis, age ≥50 years (p = .004), peritoneal cancer index (PCI) ≤ 8 (p = .049) and CA-125 < 100 (p = .02) were associated with long-term survival. There was a trend towards an association between higher CC-score and long-term survival (p = .057).
CONCLUSION: Age ≥50 years, PCI ≤8 and CA125 < 100 were associated with long-term survival in univariate analysis. There was a trend towards the significance of CC-score. Platinum-status was not associated with long-term survival.

Entities:  

Keywords:  CA125; Ovarian cancer; hyperthermic intraperitoneal chemotherapy; long-term survivor; peritoneal cancer index; survival

Mesh:

Year:  2018        PMID: 30295114     DOI: 10.1080/02656736.2018.1518544

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  5 in total

1.  Quality Indicators and Survival Outcome in Stage IIIB-IVB Epithelial Ovarian Cancer Treated at a Single Institution.

Authors:  Inga Steinberga; Kjell Jansson; Bengt Sorbe
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

Review 2.  Narrative review of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced ovarian cancer: a critical reappraisal of the current evidence.

Authors:  John Spiliotis; Anastasia Prodromidou
Journal:  J Gastrointest Oncol       Date:  2021-04

3.  Prolonged Exposition with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) May Provide Survival Benefit after Cytoreductive Surgery (CRS) in Advanced Primary Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.

Authors:  Miklos Acs; Zoltan Herold; Attila Marcell Szasz; Max Mayr; Sebastian Häusler; Pompiliu Piso
Journal:  Cancers (Basel)       Date:  2022-07-06       Impact factor: 6.575

4.  Platinum resistant recurrence and early recurrence in a multi-centre cohort of patients undergoing interval cytoreductive surgery for advanced epithelial ovarian cancer.

Authors:  Aditi Bhatt; Snita Sinukumar; Vahan Kepenekian; Praveen Kammar; Sanket Mehta; Sakina Shaikh; Witold Gertych; Naoual Bakrin; Olivier Glehen
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

5.  Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study.

Authors:  Xiaoli He; Li Wei; Rui Li; Shuang Jing; Linlin Jia; Danwei Ji; Yali Li; Yue Wang; Yongxia Zhu
Journal:  BMC Cancer       Date:  2021-06-27       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.